z-logo
open-access-imgOpen Access
Role of Botulinum Toxin Injection in Non Allergic Non Infectious Chronic Rhinosinusitis (A Systematic Review)
Author(s) -
Ossama Mansour,
Tarek A. Hamdy,
Ahmed N. Abdelhamid,
Iman Hussein
Publication year - 2020
Publication title -
qjm
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.427
H-Index - 118
eISSN - 1460-2725
pISSN - 1460-2393
DOI - 10.1093/qjmed/hcaa047.021
Subject(s) - medicine , rhinorrhea , dermatology , botulinum toxin , rhinology , nasal administration , nose , sinusitis , paranasal sinuses , surgery , otorhinolaryngology , immunology
Botulinum toxin is derived from clostridium botulinum, in the recent era it has been used in many aspects of medicine such as sialorrhea, aesthetic surgery and most recently in rhinosinusitis. Rhinosinusitis is defined as an inflammation of the membranes lining the nose and paranasal sinuses, characterized by nasal symptoms including itching, rhinorrhea and nasal obstruction. Rhinosinusitis represents a global health problem affecting between 10% and 25% of the world population. Aim of the Work Systematic review of the clinical trials, to detect the efficacy of using botulinum toxin locally in cases of non-allergic non-infectious rhinosinusitis and allergic rhinosinusitis. Methodology This is a meta-analysis study. The study included published medical articles about botulinum toxin injection for patients suffering from non-allergic non-infectious rhinosinusitis (NANIR) and patients complaining of allergic rhinosinusitis through searching the Medline data base. Results 172 patients were included in our systematic review, where botulinum toxin was used locally in the nasal cavity, a clear symptomatologic benefit of BTX on both (NANIR) and allergic rhinosinusitis in terms of rhinorrhea, pruritis, sneezing, nasal obstruction. No systemic effects were reported, and 6 cases only reported epistaxis for 1week after BTX injection. Conclusion The available data favors the efficacy of usage of botulinum toxin for cases of (NANIR) and allergic rhinosinusitis, further randomized controlled studies must be conducted in the future.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom